Enthera Pharmaceuticals Will Present Preclinical Data on Ent001, an Anti-TMEM219 Antibody in Development For The Treatment Of Ulcerative Colitis at The European Crohn’s And Colitis Organization 2024 Annual Meeting

Enthera Pharmaceuticals (“Enthera”), a clinical-stage biotech company developing first-in-class antibody therapeutics targeting the Insulin Growth Factor Binding Protein (IGFBP) family for selected inflammatory diseases, confirms its attendance at the European Crohn´s and Colitis Organization – ECCO’24 (ecco-ibd.eu) Conference, scheduled to take place in Stockholm from February 21st to 24th.

Enthera will be presenting new preclinical data demonstrating mucosal healing of the GI tract following treatment with our first-in-class anti-TMEM219 monoclonal antibody, Ent001.

Enthera will be participating in the guided poster session on Friday, the 23rd of February, where our poster (P171) entitled “Rescuing Intestinal Stem Cells via TMEM219 inhibition promotes mucosal healing in Crohn’s disease” will be showcased.

“We are pleased to share the compelling preclinical data with Ent001 in the DSS colitis model that demonstrates significant mucosal healing with both prophylactic and therapeutic dosing regimens. Ent001 offers a potenfial new treatment option for inflammatory bowel disease and is currently being studied in a multiple ascending dose study in ulcerative colitis” said Lisa M. Olson, CEO.

About Enthera Pharmaceuticals
Enthera Srl is a clinical-stage biotech company developing first-in-class antibody therapeutics to transform the treatment paradigm in inflammatory bowel diseases (IBD) and type 1 diabetes (T1D) by re-establishing stem cell capabilities. Enthera’s pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in stem cell and beta cell apoptosis in the gut and pancreas, respectively. Enthera’s lead program, Ent001, which is currently in Phase 1 clinical development, has the potential to restore the original intestinal mucosal structure in IBD and the endogenous pancreatic stem cell compartment in T1D, resulting in the restoration of organ function.

Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof. Paolo Fiorina and Dr. Francesca D’Addio with BiovelocITA, Italy’s first biotech accelerator. Enthera’s discovery engine and assets are protected by a broad portfolio of patents. The company is backed by Sofinnova Partners, AbbVie Ventures, JDRF T1D Fund, Roche Venture Fund, and several private investors.

For further information: www.entherapharmaceuticals.com

Enthera Pharmaceuticals
Lisa M. Olson Ph.D., CEO